The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

Name: Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC
Uploaded: 2020-07-03T16:03:36Z
Duration: 3 min 34 s
Description: Jason Redman, MD, National Cancer Institute, Bethesda, MD, discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Jason Redman • 3 Jul 2020

ESMO WCGIC 2020

Colorectal Cancer Gastrointestinal Cancer Ad-CEA Antibodies Avelumab mFOLFOX6

Jason Redman, MD, National Cancer Institute, Bethesda, MD, discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).